US regulators approved Eisai and Biogen’s Alzheimer’s drug lecanemab, a landmark moment for the disease and a second chance for the companies after their drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.